Development and possible clinical use of antagonists for PDGF and TGF-β

Upsala Journal of Medical Sciences

Volumn 109, Issue 3, 2004, Pages 165-178

  Heldin, Carl Henrik ^a,b,c  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Sweden)

^b Ludvig Institute for Cancer Research   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C; PLATELET DERIVED GROWTH FACTOR; PROTEIN GRB2; PROTEIN KINASE C; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; RECEPTOR BLOCKING AGENT; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANGIOGENESIS; ARTICLE; ATHEROSCLEROSIS; AUTOPHOSPHORYLATION; BREAST CANCER; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL GROWTH; CELL MOTILITY; CELL SURVIVAL; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; DERMATOFIBROSARCOMA PROTUBERANS; DIMERIZATION; EMBRYO DEVELOPMENT; ENZYME ACTIVITY; FIBROSIS; GASTROINTESTINAL STROMAL TUMOR; GENE ACTIVITY; GENE EXPRESSION; GENE INACTIVATION; GLIOBLASTOMA; GLIOMA; GLOMERULONEPHRITIS; HUMAN; HYPEREOSINOPHILIC SYNDROME; KIDNEY DEVELOPMENT; LIVER CIRRHOSIS; LUNG FIBROSIS; MELANOMA; MOLECULAR INTERACTION; MYELOFIBROSIS; NONHUMAN; PERICYTE; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MOTIF; RECEPTOR BINDING; TRANSCRIPTION REGULATION; TUMOR GROWTH; TUMOR VOLUME; WOUND HEALING;

EID: 5144226551     PISSN: 03009734     EISSN: None     Source Type: Journal    
DOI: 10.3109/2000-1967-083     Document Type: Article

References (63)

1. Heldin C-H, Eriksson U, Östman A (2002). New members of the platelet-derived growth factor family of mitogens. Arch. Biochem. Biophys. 398: 284-290.
2. Heldin C-H, Östman A, Rönnstrand L (1998). Signal transduction via platelet-derived growth factor receptors. Biochim. Biophys. Acta 1378: F79-F113.
3. Levéen P, Pekny M, Gebre-Medhin S, Swolin B, Larsson E, Betsholtz C (1994). Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities. Genes Dev. 8: 1875-1887.
4. Soriano P (1994). Abnormal kidney development and hematological disorders in PDGF β-receptor mutant mice. Genes Dev. 8: 1888-1896.
5. Lindahl P, Johansson BR, Levéen P, Betsholtz C (1997). Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277: 242-245.
6. Boström H, Willetts K, Pekny M, Levéen P, Lindahl P, Hedstrand H, Pekna M, Hellström M, Gebre-Medhin S, Schalling M, Nilsson M, Kurland S, Törnell J, Heath JK, Betsholtz C (1996). PDGF-A signaling is a critical event in lung alveolar myofibroblast development and alveogenesis. Cell 85: 863-873.
7. Karlsson L, Lindahl P, Heath JK, Betsholtz C (2000). Abnormal gastrointestinal development in PDGF-A and PDGFR-α deficient mice implicates a novel mesenchymal structure with putative instructive properties in villus morphogenesis. Development 127: 3457-3466.
8. Soriano P (1997). The PDGFα receptor is required for neural crest cell development and for normal patterning of the somites. Development 124: 2691-2700.
9. Robson MC, Phillips LG, Thomason A, Robson LE, Pierce GF (1992). Platelet-derived growth factor BB for the treatment of chronic pressure ulcers. Lancet 339: 23-25.
10. Rodt SÅ, Åhlén K, Berg A, Rubin K, Reed RK (1996). A novel physiological function for platelet-derived growth factor-BB in rat dermis. J. Physiol. 495: 193-200.
11. Ross R (1999). Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340: 115-126.
12. Heldin C-H, Westermark B (1999). Mechanism of action and in vivo role of platelet-derived growth factor. Physiol. Rev. 79: 1283-1316.
13. Pietras K, Sjöblom T, Rubin K, Heldin C-H, Östman A (2003). PDGF receptors as cancer drug targets. Cancer Cell 3: 439-443.
14. sis of simian sarcoma virus. Nature (London) 304: 35-39.
15. Doolittle RF, Hunkapiller MW, Hood LE, Devare SD, Robbins KC, Aaronson SA, Antoniades HN (1983). Simian sarcoma virus onc gene, v-sis, is derived from the gene (or genes) encoding a platelet-derived growth factor. Science 221: 275-277.
16. Hermanson M, Funa K, Hartman M, Claesson-Welsh L, Heldin C-H, Westermark B, Nistér M (1992). Platelet-derived growth factor and its receptors in human glioma tissue: Expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res. 52: 3213-3219.
17. Smits A, Funa K, Vassbotn FS, Beausang-Linder M, af Ekenstam F, Heldin C-H, Westermark B, Nistér M (1992). Expression of platelet-derived growth factor and its receptors in proliferative disorders of fibroblastic origin. Am. J. Pathol. 140: 639-648.
18. Deinhardt F (1980). The biology of primate retrovirus. In: G Klein (ed. Viral Oncology. Raven Press, New York, pp. 359-398.
19. Uhrbom L, Hesselager G, Nistér M, Westermark B (1998). Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus. Cancer Res. 58: 5275-5279.
20. Simon M-P, Pedeutour F, Sirvent N, Grosgeorge J, Minoletti F, Coindre J-M, Terrier-Lacombe M-J, Mandahl N, Graver RD, Blin N, Sozzi G, Turc-Carel C, O'Brien KP, Kedra D, Fransson I, Guilbaud C, Dumanski JP (1997). Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nature Genet. 15: 95-98.
21. Greco A, Fusetti L, Villa R, Sozzi G, Minoletti F, Mauri P, Pierotti MA (1998). Transforming activity of the chimeric sequence formed by the fusion of collagen gene COL1A1 and the platelet derived growth factor b-chain gene in dermatofibrosarcoma protuberans. Oncogene 17: 1313-1319.
22. Shimizu A, O'Brien KP, Sjöblom T, Pietras K, Buchdunger E, Collins VP, Heldin C-H, Dumanski JP, Östman A (1999). The dermatofibrosarcoma protuberans-associated collagen type Iα1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res. 59: 3719-3723.
23. Carroll M, Tomasson MH, Barker GF, Golub TR, Gilliland DG (1996). The TEL/platelet-derived growth factor β receptor (PDGFβR) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGFbR kinase-dependent signaling pathways. Proc. Natl. Acad. Sci. USA 93: 14845-14850.
24. Jousset C, Carron C, Boureux A, Quang CT, Oury C, Dusanter-Fourt I, Charon M, Levin J, Bernard O, Ghysdael J (1997). A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL-PDGFRβ oncoprotein. EMBO J. 16: 69-82.
25. Sjöblom T, Boureux A, Rönnstrand L, Heldin C-H, Ghysdael J, Östman A (1999). Characterization of the chronic myelomonocytic leukemia associated TEL-PDGFβR fusion protein. Oncogene 18: 7055-7062.
26. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG (2003). A tyrosine kinase created by fusion of the PDGFRA and FIPIL1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348: 1201-14.
27. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD, Fletcher JA (2003). PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299: 708-710.
28. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA (2003). Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21: 4342-4349.
29. Fleming TP, Saxena A, Clark WC, Robertson JT, Oldfield EH, Aaronson SA, Ali IU (1992). Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res. 52: 4550-4553.
30. Kumabe T, Sohma Y, Kayama T, Yoshimoto T, Yamamoto T (1992). Amplification of α-platelet-derived growth factor receptor gene lacking an exon coding for a portion of the extracellular region in a primary brain tumor of glial origin. Oncogene 7: 627-633.
31. Crosby JR, Seifert RA, Soriano P, Bowen-Pope DF (1998). Chimaeric analysis reveals role of PDGF receptors in all muscle lineages. Nat. Genet. 18: 385-388.
32. Furuhashi M, Sjöblom T, Abramsson A, Ellingsen J, Micke P, Li H, Bergsten-Folestad E, Eriksson U, Heuchel R, Betsholtz C, Heldin C-H, Östman A (2004). PDGF production by B16 melanoma cells leads to increased pericyte coverage of vessels and an associated increase in tumor growth rate. Cancer Res. (in press).
33. Jain RK (1987). Transport of molecules in the tumor interstitium: a reivew. Cancer Res. 47: 3039-3051.
34. Pietras K, Östman A, Sjöquist M, Buchdunger E, Reed RK, Heldin C-H, Rubin K (2001). Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 61: 2929-2934.
35. Östman A, Heldin C-H (2001). Involvement of platelet-derived growth factor in disease: development of specific antagonists. Adv. Cancer Res. 80: 1-38.
36. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M (2001). Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344: 1038-1042.
37. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL (2001). Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344: 1031-1037.
38. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S, Nielsen OS (2001). Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358: 1421-1423.
39. Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, Chase A, Chessells JM, Colombat M, Dearden CE, Dimitrijevic S, Mahon FX, Marin D, Nikolova Z, Olavarria E, Silberman S, Schultheis B, Cross NC, Goldman JM (2002). Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N. Engl. J. Med. 347: 481-487.
40. Maki RG, Awan RA, Dixon RH, Jhanwar S, Antonescu CR (2002). Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int. J. Cancer 100: 623-626.
41. Rubin BP, Schuetze SM, Eary JF, Norwood TH, Mirza S, Conrad EU, Bruckner JD (2002). Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J. Clin. Oncol. 20: 3586-3591.
42. Kilic T, Alberta JA, Zdunek PR, Acar M, Iannarelli P, O'Reilly T, Buchdunger E, Black PM, Stiles CD (2000). Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res. 60: 5143-5150.
43. Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP, Menger MD, Ullrich A, Vajkoczy P (2004). Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. Faseb J 18: 338-40.
44. Pietras K, Rubin K, Sjöblom T, Buchdunger E, Sjöquist M, Heldin C-H, Östman A (2002). Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res. 62: 5476-5484.
45. Moustakas A, Souchelnytskyi S, Heldin C-H (2001). Smad regulation in TGF-β signal transduction. J. Cell Sci. 114: 4359-4369.
46. Shi Y, Massagué J (2003). Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 113: 685-700.
47. ten Dijke P, Miyazono K, Heldin C-H (2000). Signaling inputs converge on nuclear effectors in TGF-β signaling. Trends. Biol. Sci. 25: 64-70.
48. Derynck R, Zhang YE (2003). Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425: 577-84.
49. ten Dijke P, Goumans M-J, Itoh F, Itoh S (2002). Regulation of cell proliferation by Smad proteins. J. Cell. Physiol. 191: 1-16.
50. Goumans MJ, Mummery C (2000). Functional analysis of the TGFb receptor/Smad pathway through gene ablation in mice. Int. J. Dev. Biol. 44: 253-265.
51. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B, Brattain M, Willson JKV (1995). Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science 268: 1336-1338.
52. Hahn SA, Schutte M, Hoque ATMS, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE (1996). DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271: 350-353.
53. Siegel PM, Massagué J (2003). Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nat. Rev. Cancer 3: 807-821.
54. Cui W, Fowlis DJ, Bryson S, Duffie E, Ireland H, Balmain A, Akhurst RJ (1996). TGFβ1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 86: 531-542.
55. Bandyopadhyay A, Zhu Y, Malik SN, Kreisberg J, Brattain MG, Sprague EA, Luo J, Lopez-Casillas F, Sun LZ (2002). Extracellular domain of TGFβ type III receptor inhibits angiogenesis and tumor growth in human cancer cells. Oncogene 21: 3541-3551.
56. Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, Easterly E, Roebuck LR, Ryan S, Gotwals PJ, Koteliansky V, Arteaga CL (2002). Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases. J. Clin. Invest. 109: 1551-1559.
57. Yang YA, Dukhanina O, Tang B, Mamura M, Letterio JJ, MacGregor J, Patel SC, Khozin S, Liu ZY, Green J, Anver MR, Merlino G, Wakefield LM (2002). Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects. J. Clin. Invest. 109: 1607-1615.
58. Callahan JF, Burgess JL, Fornwald JA, Gaster LM, Harling JD, Harrington FP, Heer J, Kwon C, Lehr R, Mathur A, Olson BA, Weinstock J, Laping NJ (2002). Identification of novel inhibitors of the transforming growth factor b1 (TGF-β1) type 1 receptor (ALK5). J. Med. Chem. 45: 999-1001.
59. DaCosta Byfield S, Major C, Laping NJ, Roberts AB (2004). SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7. Mol. Pharmacol. 65: 744-752.
60. Inman GJ, Nicolas FJ, Callahan JF, Marling JD, Gaster LM, Reith AD, Laping NJ, Hill CS (2002). SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol. Pharmacol. 62: 65-74.
61. Laping NJ, Grygielko E, Mathur A, Butter S, Bomberger J, Tweed C, Martin W, Fornwald J, Lehr R, Harling J, Gaster L, Callahan JF, Olson BA (2002). Inhibition of transforming growth factor (TGF)-β1-induced extracellular matrix with a novel inhibitor of the TGF-β type I receptor kinase activity: SB-431542. Mol. Pharmacol. 62: 58-64.
62. Kurisaki K, Kurisaki A, Valcourt U, Terentiev AA, Pardali K, ten Dijke P, Heldin C-H, Ericsson J, Moustakas A (2003). Nuclear factor YY1 inhibits transforming growth factor β- and bone morphogenetic protein-induced cell differentiation. Mol. Cell. Biol. 23: 4494-4510.
63. Capdeville R, Buchdunger E, Zimmermann J, Matter A (2002). Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 1: 493-502.